SEC Form 4 · accession 0001209191-19-002394
Phio Pharmaceuticals Corp. · PHIO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Geert Cauwenbergh
Officer — Chief Executive Officer · Director
Period of report
Jan 4, 2019
Accepted (ET)
Jan 7, 2019 · 9:14 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001533040
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common stock, $0.0001 par value | Jan 4, 2019 | A | 23,139 | $0.3499 | A | 261,699 | D | |
| Common stock, $0.0001 par value | holding | — | — | — | 450 | I | By spouse |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1As reported on the Current Report on Form 8-K filed on September 4, 2018 and December 21, 2018, the reporting person has elected to receive a portion of his compensation in stock in lieu of cash. Accordingly, on January 4, 2019, the reporting person received a total of 23,139 shares of common stock from the Company in lieu of $8,096.16 of cash compensation, which includes base salary, that was payable on such date.